The Invesco S&P SmallCap Health Care ETF (PSCH) seeks to track the S&P SmallCap 600 Health Care Index, which measures the performance of small-capitalization healthcare companies within the S&P SmallCap 600 universe. This sector-focused equity ETF provides targeted exposure to emerging healthcare innovators, medical device manufacturers, biotechnology firms, and pharmaceutical companies with market capitalizations typically between $700 million and $3.2 billion.
How It Works
PSCH uses a passively managed, market-capitalization-weighted approach that mirrors its benchmark index composition. The fund holds all constituent stocks in proportion to their market value within the small-cap healthcare sector, with larger companies receiving proportionally higher allocations. Rebalancing occurs quarterly to maintain alignment with index changes and sector classifications. The ETF typically holds 60-80 small-cap healthcare companies, providing concentrated exposure to this specialized market segment while maintaining diversification within the healthcare sector.
Key Features
- Pure-play exposure to small-cap healthcare innovation, capturing emerging companies often overlooked by broad market ETFs
- Focuses on S&P SmallCap 600 universe, ensuring quality screening and minimum liquidity requirements for underlying holdings
- Concentrated portfolio of 60-80 holdings allows meaningful exposure to individual company growth stories within healthcare sector
Risks
- This ETF can lose significant value during healthcare sector selloffs or regulatory concerns, potentially declining 40-50% during biotech bear markets
- Small-cap healthcare stocks face heightened volatility from clinical trial results, FDA approvals, and drug development setbacks affecting individual companies
- Concentrated sector exposure means the fund lacks diversification benefits, moving dramatically with healthcare-specific news rather than broader market trends
Who Should Own This
Best suited as a satellite holding (5-15% of equity allocation) for aggressive growth investors with 3+ year time horizons seeking targeted small-cap healthcare exposure. High risk tolerance required due to sector concentration and small-cap volatility. Appropriate for investors comfortable with biotech cycles and regulatory risks who want to capitalize on healthcare innovation beyond large pharmaceutical companies.